In support of this notion, exploration of data from genomics of drug sensitivity in cancer database showed that loss-of-function mutation of RB1 had highest rank in driving CDK4/6i (palbociclib) resistance across hundreds of cancer cell lines (Supplementary Fig. 1b). Here, CDK4 is linked to cancer.